24 citations
,
July 2021 in “Pharmaceutics” This article reviews the JAK signaling pathway and the development of ruxolitinib cream as a targeted treatment for inflammatory skin diseases, reporting no new clinical results.
1 citations
,
October 2025 in “Journal of Investigative Dermatology” In this study of women with frontal fibrosing alopecia, delgocitinib cream improved the molecular signature of lesions and demonstrated potential as a treatment, showing significant transcriptomic changes and some clinical improvements over 12 weeks compared to a cream vehicle.
June 2026 in “Saudi Medical Horizons Journal” This review discusses the role of JAK inhibitors in treating atopic dermatitis, alopecia areata, and vitiligo, highlighting their effectiveness and safety considerations but stressing the need for further research on long-term safety and patient selection.
November 2025 in “Journal of Investigative Dermatology” Combining MMP-9 and JAK inhibitors can effectively prevent skin depigmentation in vitiligo.
6 citations
,
May 2024 in “JAAD Case Reports” This study highlights that topical ruxolitinib cream is FDA-approved for mild to moderate atopic dermatitis and nonsegmental vitiligo in patients aged 12 and older, but its use in other skin conditions like frontal fibrosing alopecia remains under-researched and needs further exploration in clinical practice.